Tango Therapeutics (TNGX) Projected to Post Quarterly Earnings on Tuesday

Posted by Geri Gentry on Jul 28th, 2026

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) is expected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.31) per share and revenue of $1.5620 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:00 AM ET.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, meeting analysts’ consensus estimates of ($0.32). On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Trading Up 0.3%

Shares of TNGX stock opened at $26.72 on Tuesday. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of -32.19 and a beta of 1.12. The business’s 50-day moving average price is $27.20 and its 200-day moving average price is $20.82. Tango Therapeutics has a 12 month low of $5.77 and a 12 month high of $34.39.

Insider Buying and Selling

In related news, insider Adam Crystal sold 27,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the sale, the insider directly owned 115,743 shares in the company, valued at $3,424,835.37. This represents a 18.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 81,000 shares of company stock valued at $1,989,630 in the last quarter. Corporate insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new stake in shares of Tango Therapeutics during the fourth quarter worth $335,000. VARCOV Co. acquired a new position in Tango Therapeutics in the fourth quarter valued at $261,000. Virtus Investment Advisers LLC lifted its holdings in Tango Therapeutics by 26.3% in the fourth quarter. Virtus Investment Advisers LLC now owns 28,452 shares of the company’s stock valued at $252,000 after buying an additional 5,920 shares during the period. Tudor Investment Corp ET AL boosted its position in Tango Therapeutics by 27.4% during the fourth quarter. Tudor Investment Corp ET AL now owns 68,251 shares of the company’s stock valued at $605,000 after acquiring an additional 14,679 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in Tango Therapeutics during the fourth quarter valued at $4,825,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on TNGX shares. Mizuho lifted their target price on shares of Tango Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. B. Riley Financial restated a “buy” rating on shares of Tango Therapeutics in a research report on Monday, June 8th. JPMorgan Chase & Co. started coverage on shares of Tango Therapeutics in a report on Wednesday, July 15th. They set an “overweight” rating and a $46.00 price target on the stock. Citigroup reissued a “buy” rating on shares of Tango Therapeutics in a research note on Monday, April 27th. Finally, Canaccord Genuity Group increased their price objective on Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, June 29th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.15.

Check Out Our Latest Research Report on TNGX

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.